Artemisinin-based combination therapy for ... - The Cochrane Library

More documents

Recommendations

Info

$Interventions for treating proximal humeral fractures in adults (Review)$

A C K N O W L E D G E M E N T S This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries. We thank Hasifa Bukirwa for assistance with data extraction. References to studies included in this review Adjei 2006 GHA {published data only} Adjei GO, Kurtzhals JAL, Rodrigues OP, Alifrangis M, Hoegberg LCG, Kitcher ED, et al.Amodiaquine-artesunate vs artemetherlumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malaria Journal 2008;7(127):DOI: 10.1186/1475-2875-7-127. Ashley 2003a THA {published and unpublished data} Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, et al.Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Journal of Infectious Diseases 2004; Vol. 190, issue 10:1773–82. Ashley 2003b THA {published and unpublished data} Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, et al.Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Journal of Infectious Diseases 2004;190(10):1773–82. Ashley 2004 THA {published and unpublished data} Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, et al.A randomized, controlled study of a simple, oncedaily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clinical Infectious Diseases 2005; Vol. 41, issue 4:425–32. Ashley 2005 THA {published and unpublished data} Ashley EA, Lwin K, McGready R, Simon WH, Phaiphun L, Proux S, et al.An open label randomized comparison of mefloquineartesunate as separate tablets vs. a new co-formulatedcombination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Tropical Medicine and International Health 2006;11(11):1653–60. Bonnet 2004 GIN {published and unpublished data} Bonnet M, Roper C, Felix M, Coulibaly L, Kankolongo GM, Guthmann JP. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N’Zerekore. Malaria Journal 2007; Vol. 6:54. Bousema 2004 KEN {published and unpublished data} Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, Houben R, et al.Moderate Effect of Artemisinin-Based Combination Therapy on Transmission of Plasmodium falciparum. Journal of Infectious Diseases 2006; Vol. 193, issue 8:1151–9. R E F E R E N C E S Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Bukirwa 2005 UGA {published data only} Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al.Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clinical Trials 2006; Vol. 1, issue 1:e7. Djimde 2004 MLI {published and unpublished data} Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al.Efficacy, Safety, and Selection of Molecular Markers of Drug Resistance by Two ACTs in Mali. American Journal of Tropical Medicine and Hygiene 2008; Vol. 78, issue 3:455–61. Dorsey 2006 UGA {published and unpublished data} Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al.Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; Vol. 297, issue 20:2210–9. Falade 2005 NGA {published data only} Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM. High efficacy of two artemisinin-based combinations (artemetherlumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Tropical Medicine and International Health 2008;13(5):635–643. Fanello 2004 RWA {published data only} Fanello CI, Karema C, van Doren W, Van Overmeir C, Ngamije D, D’Alessandro U. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007; Vol. 101, issue 4:344–50. Faye 2003 SEN {published and unpublished data} Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malaria Journal 2007; Vol. 6, issue 1:80. Grande 2005 PER {published data only} Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, et al.A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS ONE 2007; Vol. 2, issue 10:e1101. Guthmann 2003 AGO {published and unpublished data} Guthmann JP, Ampuero J, Fortes F, van Overmeir C, Gaboulaud V, Tobback S, et al.Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in 30
Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg 2005; Vol. 99, issue 7:485–92. Guthmann 2004 AGO {published data only} Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, et al.High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. American Journal of Tropical Medicine and Hygiene 2006; Vol. 75, issue 1:143–5. Hamour 2003 SDN {published data only} Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, et al.Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxinepyrimethamine and artesunate plus amodiaquine combinations. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005; Vol. 99, issue 7:548–54. Hasugian 2005 IDN {published and unpublished data} Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al.Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases 2007; Vol. 44, issue 8:1067–74. Hutagalung 2002 THA {published data only} Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, Thwai KL, et al.A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malaria Journal 2005; Vol. 4:46. Janssens 2003 KHM {published data only} Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, et al.A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health 2007; Vol. 12, issue 2:251–9. Kamya 2006 UGA {published data only} Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al.Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clinical Trials 2007; Vol. 2, issue 5:e20. Karema 2004 RWA {published and unpublished data} Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, et al.Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; Vol. 100, issue 12:1105–11. Karunajeewa 2007 PNG {published data only} Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al.A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 2008;359 (24):2545–57. Kayentao 2006 MLI {published data only} Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, et al.Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment Artemisinin-based combination therapy for treating uncomplicated malaria (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. of uncomplicated malaria in Faladje, Mali. Malaria Journal 2009;8: 5. Kobbe 2007 GHA {published data only} Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H, et al.A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malaria Journal 2008;7:261. Koram 2003 GHA {published data only} Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Tropica 2005; Vol. 95, issue 3:194–203. Lefevre 1999 THA {published data only} Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, et al.A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene 2001; Vol. 64, issue 5–6:247–56. Martensson 2003 TZA {published data only} Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al.Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clinical Infectious Diseases 2005; Vol. 41, issue 8:1079–86. Mayxay 2003 LAO {published and unpublished data} Mayxay M, Khanthavong M, Lindegardh N, Keola S, Barends M, Pongvongsa T, et al.Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic. Clinical Infectious Diseases 2004; Vol. 39, issue 8:1139–47. Mayxay 2004 LAO {published and unpublished data} Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, Keola S, et al.An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People’s Democratic Republic (Laos). Tropical Medicine and International Health 2006; Vol. 11, issue 8:1157–65. Menard 2006 MDG {published data only} Menard D, Andrianina NN, Ramiandrasoa Z, Randriamanantena A, Rasoarilalao N, Jahevitra M, et al.Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar. Malaria Journal 2007; Vol. 6:65. Mens 2007 KEN {published data only} Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD, et al.A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malaria Journal 2008;7(237):Doi:10.1186/ 1475–2875-7-237. 31
Page 1 and 2: Artemisinin-based combination thera
Page 3 and 4: Analysis 2.2. Comparison 2 Dihydroa
Page 5 and 6: Analysis 10.5. Comparison 10 Arteme
Page 7 and 8: [Intervention Review] Artemisinin-b
Page 9 and 10: B A C K G R O U N D Malaria is a di
Page 11 and 12: drugs and the treatment comparisons
Page 13 and 14: this analysis into participants who
Page 15 and 16: Figure 1. Methodological quality su
Page 17 and 18: confidence intervals of the estimat
Page 19 and 20: Anaemia Hasugian 2005 IDN found tha
Page 21 and 22: Three trials report significantly m
Page 23 and 24: or those treated for P. vivax at ba
Page 25 and 26: Early vomiting Not reported. D I S
Page 27 and 28: Figure 4. Olliaro-Vaillant plot. Da
Page 33 and 34: Figure 10. Olliaro-Vaillant plot. D
Page 35: of findings tables’. For these ta
Page 39 and 40: References to studies excluded from
Page 41 and 42: Adjuik 2004 Adjuik M, Babiker A, Ga
Page 43 and 44: C H A R A C T E R I S T I C S O F S
Page 45 and 46: Ashley 2003a THA (Continued) Outcom
Page 47 and 48: Ashley 2003b THA (Continued) Alloca
Page 49 and 50: Ashley 2005 THA (Continued) Exclusi
Page 51 and 52: Bonnet 2004 GIN (Continued) Item Au
Page 53 and 54: Bukirwa 2005 UGA Methods Trial desi
Page 55 and 56: Djimde 2004 MLI (Continued) • AS
Page 57 and 58: Dorsey 2006 UGA (Continued) Item Au
Page 59 and 60: Fanello 2004 RWA Methods Trial desi
Page 61 and 62: Faye 2003 SEN (Continued) Outcomes
Page 63 and 64: Grande 2005 PER (Continued) Allocat
Page 65 and 66: Guthmann 2004 AGO (Continued) All d
Page 67 and 68: Hasugian 2005 IDN Methods Trial des
Page 69 and 70: Hutagalung 2002 THA (Continued) 5.
Page 71 and 72: Janssens 2003 KHM (Continued) Free
Page 73 and 74: Karema 2004 RWA (Continued) Interve
Page 75 and 76: Karunajeewa 2007 PNG (Continued) Ri
Page 77 and 78: Kobbe 2007 GHA (Continued) Exclusio
Page 79 and 80: Koram 2003 GHA (Continued) Adequate
Page 81 and 82: Martensson 2003 TZA Methods Trial d
Page 83 and 84: Mayxay 2003 LAO (Continued) 1. Feve
Page 85 and 86: Menard 2006 MDG Methods Trial desig
Page 87 and 88:
Mens 2007 KEN (Continued) Risk of b
Page 89 and 90:
Mutabingwa 2004 TZA (Continued) •
Page 91 and 92:
Owusu-Agyei 2006 GHA (Continued) Fr
Page 93 and 94:
Sagara 2005b MLI (Continued) • 25
Page 95 and 96:
Smithuis 2004 MMR (Continued) Risk
Page 97 and 98:
Stohrer 2003 LAO Methods Trial desi
Page 99 and 100:
Swarthout 2004 ZAR (Continued) Note
Page 101 and 102:
Tran 2002 VNM Methods Trial design:
Page 103 and 104:
Van den Broek 2003a BGD (Continued)
Page 105 and 106:
Van Vugt 1998 THA Methods Trial des
Page 107 and 108:
Yeka 2004 UGA (Continued) Risk of b
Page 109 and 110:
Yeka 2007 UGA (Continued) Free of o
Page 111 and 112:
Zongo 2007 BFA (Continued) Novartis
Page 113 and 114:
(Continued) Fofana 2005 Conference
Page 115 and 116:
D A T A A N D A N A L Y S E S Compa
Page 117 and 118:
2.2 Asia 1 317 Risk Ratio (M-H, Fix
Page 119 and 120:
Comparison 5. Dihydroartemisinin-pi
Page 121 and 122:
Comparison 8. Artesunate plus meflo
Page 123 and 124:
Comparison 10. Artemether-lumefantr
Page 125 and 126:
Comparison 12. Artesunate plus amod
Page 127 and 128:
5.2 DHA-P 3 doses 3 1116 Risk Ratio
Page 129 and 130:
Comparison 21. How does Artesunate
Page 131 and 132:
Analysis 1.3. Comparison 1 Dihydroa
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
(... Continued) Study or subgroup D
Page 139 and 140:
Analysis 1.12. Comparison 1 Dihydro
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
(... Continued) Study or subgroup A
Page 165 and 166:
Analysis 6.6. Comparison 6 Artesuna
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Analysis 9.2. Comparison 9 Artemeth
Page 175 and 176:
Page 177 and 178:
Analysis 9.8. Comparison 9 Artemeth
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Analysis 10.2. Comparison 10 Arteme
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Analysis 12.2. Comparison 12 Artesu
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Analysis 14.2. Comparison 14 Dihydr
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Analysis 20.1. Comparison 20 How do
Page 221 and 222:
Analysis 21.1. Comparison 21 How do
Page 223 and 224:
(Continued) 2. How does artesunate
Page 225 and 226:
(Continued) Sensitivity analysis 1
Page 227 and 228:
(Continued) Smithuis 2004 MMR (652
Page 229 and 230:
Dihydroartemisinin-piperaquine vs A
Page 231 and 232:
(Continued) Mayxay 2003 LAO (220 pa
Page 233 and 234:
Artesunate plus mefloquine vs Amodi
Page 235 and 236:
(Continued) Faye 2003 SEN (509 part
Page 237 and 238:
Artemether-lumefantrine vs Artesuna
Page 239 and 240:
(Continued) Zongo 2005 BFA (521 par
Page 241 and 242:
(Continued) Faye 2003 SEN (521 part
Page 243 and 244:
PCR = polymerase chain reaction PCV
Page 245 and 246:
(Continued) Proportion with anaemia
Page 247 and 248:
(Continued) Vivax efficacy: P. viva
Page 249 and 250:
(Continued) Efficacy: Total Failure
Page 251 and 252:
(Continued) Outcomes Illustrative c
Page 253 and 254:
Page 255 and 256:
(Continued) GRADE Working Group gra
Page 257 and 258:
Footnotes 1 Data were also availabl
Page 259 and 260:
8 Very serious imprecision: There w
Page 261 and 262:
Page 263 and 264:
(Continued) justed Vivax efficacy:
Page 265 and 266:
(Continued) Harms: Serious adverse
Page 267 and 268:
(Continued) Harms: Early vomiting -
Page 269 and 270:
1 Dorsey 2006 UGA; Faye 2003 SEN; K
show all

Artemisinin-based combination therapy for ... - The Cochrane Library

Create successful ePaper yourself

Delete template?

Save as template?